A multicenter, open-label, single-arm, phase 2 study of the S1P inhibitor sonepcizumab (LT1009) in patients with previously treated metastatic renal cell carcinoma (mRCC).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Beth Israel Deaconess Medical Center, City Of Hope National Medical Center, City of Hope, Medical University of South Carolina, Sarah Cannon, Tennessee Oncology, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, San Diego State University, Lpath (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2906748135